Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

The FDA Fast-Tracked Psychedelic Medicines For Depression And PTSD

The Food and Drug Administration has fast-tracked three psychedelic medicines for review, issuing priority vouchers to companies studying psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone, a compound related to MDMA, for post-traumatic stress disorder, in a development that could put the first FDA-approved psychedelic medicines on the market as soon as this summer. The vouchers compress the agency’s standard review timeline from the usual 10 to 12 months down to just one to two months, a change the FDA Commissioner said is designed to ensure that red tape does not delay treatments that show genuine promise for conditions that have been notoriously difficult to treat. The three companies that received vouchers are Compass Pathways, the nonprofit Usona Institute, and Otsuka Pharmaceutical, which is acquiring the methylone program. The action followed an executive order signed by President Trump directing the FDA to prioritize psychedelic drugs that have received Breakthrough Therapy designation, a status reserved for treatments showing early evidence of substantial improvement over existing options.

For millions of Americans with treatment-resistant depression, PTSD, and other serious mental health conditions that have not responded to available medications, the move represents a potential turning point in access to a category of medicine that has shown significant clinical results but has remained largely inaccessible for decades. Psilocybin has shown durable antidepressant effects in multiple studies, with some patients maintaining improvement for at least a year after a single treatment course. The FDA also cleared the first-ever clinical study in the United States of noribogaine, a compound derived from the ibogaine plant, as a potential treatment for alcohol use disorder, a condition that affects more than 29 million Americans. The FDA Commissioner said the first psychedelic drug could receive approval by the end of summer, and that the field is moving forward grounded in sound science and rigorous clinical standards.

Source: https://edition.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers

PrevPreviousJurassic Park Star Sam Neill Is Cancer Free
NextBanksy Just Confirmed His Latest Masterpiece, And London Is Already Crowding Around ItNext

Recent Articles

Happy News

For The First Time In History Medicare Is Covering Weight Loss Drugs And The Price Is $50 A Month

May 14, 2026

Starting July 1, 2026 eligible Medicare enrollees will be able to access GLP-1 weight loss medications including Wegovy, Zepbound, and the newer drug Foundayo for a flat $50 monthly copay, in a historic first for the program, which has never before covered anti-obesity medications despite covering many of the serious

Read More
Happy News

Swedish Scientists Just Grew The Cells Type 1 Diabetes Destroys From Scratch

May 13, 2026

Scientists at Karolinska Institutet and KTH Royal Institute of Technology in Sweden have developed a more reliable method for growing insulin-producing cells from human stem cells, and the results published in Stem Cell Reports represent one of the most encouraging steps yet toward a potential treatment for type 1 diabetes.

Read More
Happy News

New Research Reveals The Personality Trait That Predicts Whether You Will Seek Out A Cat When Stressed

May 12, 2026

A study published in the journal Anthrozoös, conducted by researchers at Washington State University and KU Leuven in Belgium, has identified the personality trait most likely to predict whether someone will seek out a cat for stress relief rather than a dog, and the answer has a name: emotionality. Researchers

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.